A phase 1 evaluation of duvelisib (IPI-145), a PI3K-δ,γ inhibitor, in patients with relapsed/refractory iNHL Meeting Abstract
| Authors: | Flinn, I.; Oki, Y.; Patel, M.; Horwitz, S. M.; Foss, F. M.; Sweeney, J.; Allen, K.; Douglas, M.; Steelman, L.; Dunbar, J.; Stern, H. M.; Kelly, P.; Kahl, B. |
| Abstract Title: | A phase 1 evaluation of duvelisib (IPI-145), a PI3K-δ,γ inhibitor, in patients with relapsed/refractory iNHL |
| Meeting Title: | 56th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 124 |
| Issue: | 21 |
| Meeting Dates: | 2014 Dec 6-9 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2014-12-06 |
| Language: | English |
| ACCESSION: | WOS:000349243500068 |
| PROVIDER: | wos |
| DOI: | 10.1182/blood.V124.21.802.802 |
| Notes: | Meeting Abstract: 802 -- 56th Annual Meeting of the American-Society-of-Hematology -- DEC 06-09, 2014 -- San Francisco, CA -- Source: Wos |
